To the full analysis
Buyback calculator for UroGen Pharma
UroGen Pharma stock: dividend
URGNUroGen Pharma does not currently pay a dividend. UroGen Pharma did not buy back any of its own shares from fiscal 2023 to 2025.
Whether UroGen Pharma Ltd. pays a dividend and what the company does with its cash instead: free cash flow, buybacks of its own shares and the share count over recent years.
Daily figure as of 13 Nov 2026
Free cash flow and buybacks
| Fiscal year | Free cash flow | Share buybacks | Shares outstanding |
|---|---|---|---|
| 2025 | −$162.73M | $0 | 48.12M |
| 2024 | −$97.06M | $0 | 42.88M |
| 2023 | −$76.57M | $0 | 28.83M |
| 2022 | −$87.81M | $0 | 22.81M |
| 2021 | −$85.64M | $0 | 22.35M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2018)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.